I step outside for 30 minutes and Raki implodes faster than IMU's share price.
IMU have shelved their internal investigations on PD1-VAXX and HER-VAXX and told holders at the AGM last year (via stream - lol) that they were looking to out license these programs due to funding constraints.
One of the reasons they have funding constraints is because they had to acquire Azer-Cel to replace these programs because they didn't produce anything of commercial significance... obviously they don't make that "Announcement". They reframe it as bolstering CF33:
You could quite easily counter my argument by linking any active and recruiting trials investigating PD1/HER-VAXX (outside of the investigator led neoPOLEM).
Too bad there aren't any...
The entirety of the B Cell platform rests on a me-too investigator led program. Sounds pretty shelved to me.
IMU Price at posting:
1.4¢ Sentiment: Sell Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)